{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&legislature.prefLabel=House%20of%20Commons&_view=AnsweredQuestions&tablingMemberConstituency=Mid%20Derbyshire&min-answer.questionFirstAnswered.=2016-12-20T10:28:45.56Z&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest,answer.groupedQuestionUIN,answer.questionFirstAnswered&_sort=tablingMemberConstituency,-answer.groupedQuestionUIN", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?legislature.prefLabel=House%20of%20Commons&_view=AnsweredQuestions&tablingMemberConstituency=Mid%20Derbyshire&min-answer.questionFirstAnswered.=2016-12-20T10:28:45.56Z&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest,answer.groupedQuestionUIN,answer.questionFirstAnswered&_sort=tablingMemberConstituency,-answer.groupedQuestionUIN", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&legislature.prefLabel=House%20of%20Commons&_view=AnsweredQuestions&tablingMemberConstituency=Mid%20Derbyshire&min-answer.questionFirstAnswered.=2016-12-20T10:28:45.56Z&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest,answer.groupedQuestionUIN,answer.questionFirstAnswered&_metadata=all&_sort=tablingMemberConstituency,-answer.groupedQuestionUIN", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&legislature.prefLabel=House%20of%20Commons&_view=AnsweredQuestions&tablingMemberConstituency=Mid%20Derbyshire&min-answer.questionFirstAnswered.=2016-12-20T10:28:45.56Z&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest,answer.groupedQuestionUIN,answer.questionFirstAnswered&_sort=tablingMemberConstituency,-answer.groupedQuestionUIN", "isPartOf" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?legislature.prefLabel=House%20of%20Commons&_view=AnsweredQuestions&tablingMemberConstituency=Mid%20Derbyshire&min-answer.questionFirstAnswered.=2016-12-20T10:28:45.56Z&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest,answer.groupedQuestionUIN,answer.questionFirstAnswered&_sort=tablingMemberConstituency,-answer.groupedQuestionUIN", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?legislature.prefLabel=House%20of%20Commons&_view=AnsweredQuestions&tablingMemberConstituency=Mid%20Derbyshire&min-answer.questionFirstAnswered.=2016-12-20T10:28:45.56Z&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest,answer.groupedQuestionUIN,answer.questionFirstAnswered&_sort=tablingMemberConstituency,-answer.groupedQuestionUIN", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&legislature.prefLabel=House%20of%20Commons&_view=AnsweredQuestions&tablingMemberConstituency=Mid%20Derbyshire&min-answer.questionFirstAnswered.=2016-12-20T10:28:45.56Z&_properties=answer.isMinisterialCorrection,legislature,legislature,registeredInterest,answer.groupedQuestionUIN,answer.questionFirstAnswered&_sort=tablingMemberConstituency,-answer.groupedQuestionUIN", "type" : "http://purl.org/linked-data/api/vocab#ListEndpoint"} , "items" : [{"_about" : "http://data.parliament.uk/resources/1239272", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1239272/answer", "answerText" : {"_value" : "
The Independent Commission for Aid Impact (ICAI) review of maternal health results in 2018 made five recommendations, including adopting a long-term approach to maternal health planning, linking strongly to health system strengthening work and increasing the focus on quality of care. We welcomed all recommendations and the 2020 follow up review acknowledged our swift progress, finding that the UK had 'enhanced its emphasis on the need for good quality, respectful care for women and their babies and increased focus on adolescents and poorer women within its new family planning programmes'. ICAI also recognised the UK Government's commitment to Ending the Preventable Deaths of Mothers, Newborns and Children by 2030 and to international advocacy for comprehensive sexual reproductive health and rights.<\/p>
Using internationally accepted methods, we estimate that the UK Government has spent an average of approximately £1 billion per year on Maternal Newborn and Child Health between 2013/14 - 2017/18, on a range of bilateral and multilateral programmes. Maternal health remains a key priority throughout our health work, with recently announced investments including £600 million to the Reproductive Health Supplies programme to buy family planning supplies for millions more women and girls in the world's poorest countries each year.<\/p>
The UK commitment to ending preventable deaths has created further momentum to ensure the right balance in the FCDO portfolio across family planning, health services and other essential interventions for maternal and newborn health and wellbeing. This holistic approach is essential if we are to maximise the impact of our money and policy, and more important than ever before given the challenges that the COVID-19 pandemic is creating for health services across the world. In responding to the ICAI recommendations, we are reviewing our approach to maternal health results to include more context based country data and to increase our focus on long-term, sustainable change.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"} } , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"} , "answeringMemberPrinted" : {"_value" : "Wendy Morton"} , "dateOfAnswer" : {"_value" : "2020-10-05", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "97555"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-10-05T16:08:22.343Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "208"} , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "date" : {"_value" : "2020-09-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Development Aid: Maternal Mortality"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what changes have been made to UK Aid spending on reducing maternal deaths which satisfactorily address the amber/red ratings for impact, effectiveness, sustainability and value for money given by the Independent Commission for Aid Impact in 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4025", "label" : {"_value" : "Biography information for Mrs Pauline Latham"} } , "tablingMemberConstituency" : {"_value" : "Mid Derbyshire"} , "tablingMemberPrinted" : [{"_value" : "Mrs Pauline Latham"} ], "uin" : "97554"} , {"_about" : "http://data.parliament.uk/resources/1239275", "AnsweringBody" : [{"_value" : "Foreign, Commonwealth and Development Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1239275/answer", "answerText" : {"_value" : "
The Independent Commission for Aid Impact (ICAI) review of maternal health results in 2018 made five recommendations, including adopting a long-term approach to maternal health planning, linking strongly to health system strengthening work and increasing the focus on quality of care. We welcomed all recommendations and the 2020 follow up review acknowledged our swift progress, finding that the UK had 'enhanced its emphasis on the need for good quality, respectful care for women and their babies and increased focus on adolescents and poorer women within its new family planning programmes'. ICAI also recognised the UK Government's commitment to Ending the Preventable Deaths of Mothers, Newborns and Children by 2030 and to international advocacy for comprehensive sexual reproductive health and rights.<\/p>
Using internationally accepted methods, we estimate that the UK Government has spent an average of approximately £1 billion per year on Maternal Newborn and Child Health between 2013/14 - 2017/18, on a range of bilateral and multilateral programmes. Maternal health remains a key priority throughout our health work, with recently announced investments including £600 million to the Reproductive Health Supplies programme to buy family planning supplies for millions more women and girls in the world's poorest countries each year.<\/p>
The UK commitment to ending preventable deaths has created further momentum to ensure the right balance in the FCDO portfolio across family planning, health services and other essential interventions for maternal and newborn health and wellbeing. This holistic approach is essential if we are to maximise the impact of our money and policy, and more important than ever before given the challenges that the COVID-19 pandemic is creating for health services across the world. In responding to the ICAI recommendations, we are reviewing our approach to maternal health results to include more context based country data and to increase our focus on long-term, sustainable change.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4358", "label" : {"_value" : "Biography information for Wendy Morton"} } , "answeringMemberConstituency" : {"_value" : "Aldridge-Brownhills"} , "answeringMemberPrinted" : {"_value" : "Wendy Morton"} , "dateOfAnswer" : {"_value" : "2020-10-05", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "97554"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-10-05T16:08:22.393Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "208"} , "answeringDeptShortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "answeringDeptSortName" : {"_value" : "Foreign, Commonwealth and Development Office"} , "date" : {"_value" : "2020-09-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Development Aid: Postnatal Care"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, with reference to the report by the Independent Commission for Aid Impact entitled Assessing DFID\u2019s Results in Improving Maternal Health, published in October 2018, what methodology he is using to measure progress against the finding that DFID\u2019s portfolio was not well balanced across family planning, health services and other interventions, so as to maximise medium-to-long-term-impact.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4025", "label" : {"_value" : "Biography information for Mrs Pauline Latham"} } , "tablingMemberConstituency" : {"_value" : "Mid Derbyshire"} , "tablingMemberPrinted" : [{"_value" : "Mrs Pauline Latham"} ], "uin" : "97555"} , {"_about" : "http://data.parliament.uk/resources/1327743", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1327743/answer", "answerText" : {"_value" : "
The Yellow Card Scheme is the system used in the United Kingdom for reporting adverse drug reactions (ADRs). This acts as an early warning system for the identification of previously unrecognised adverse reactions and also provides valuable information on recognised ADRs, allowing the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency (MHRA) to identify and refine the understanding of risk factors that may affect the clinical management of patients.<\/p>
<\/p>
The following table shows spontaneous suspected ADR reports for fluoroquinolones in association with tendon injury, mitochondrial dysfunction and oxidative stress to 25 May 2021 in the UK.<\/p>
<\/p>
Reaction<\/p><\/td> | Number of reports<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tendon disorders*<\/p><\/td> | 1,381<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
mitochondrial cytopathy, mitochondrial toxicity, mitochondrial myopathy acquired<\/p><\/td> | 1<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oxidative stress<\/p><\/td> | 2**<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Source: MHRA Sentinel database for Adverse Drug Reactions.<\/p> <\/p> Notes:<\/p> <\/p> *Tendon disorders includes 21 different relevant reaction terms.<\/p> **These reports are duplicates and have been subsequently merged on the database.<\/p> <\/p> The frequency of tendonitis range from 1 in 100 to less than 1 in 10,000, depending on the specific fluoroquinolone medicine. For the products that provide an estimate of the frequency of tendon rupture, this is listed as less than 1 in 10,000. Mitochondrial dysfunction and oxidative stress are among the possible mechanisms that might lead to tendon injury or other ADRs caused by fluoroquinolones, but this association is not fully understood and mitochondrial dysfunction and oxidative stress are not listed as ADRs in the product information for fluoroquinolones.<\/p> <\/p> The MHRA continues to review information about the safety of all medicines, including fluoroquinolones, and will take appropriate regulatory action as appropriate on the basis of new safety information. Serious side effects of fluoroquinolone antibiotics can be varied, potentially affecting several different parts of the body. An assessment of the potential merits of fluoroquinolone toxicity as a clinical diagnosis in response to tendon injury, mitochondrial dysfunction or oxidative stress has not been made.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1481", "label" : {"_value" : "Biography information for Ms Nadine Dorries"} } , "answeringMemberConstituency" : {"_value" : "Mid Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Ms Nadine Dorries"} , "dateOfAnswer" : {"_value" : "2021-06-09", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "7155"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1327743/answer/previousversion/4612", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1481", "label" : {"_value" : "Biography information for Ms Nadine Dorries"} } , "answeringMemberConstituency" : {"_value" : "Mid Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Ms Nadine Dorries"} } , "questionFirstAnswered" : [{"_value" : "2021-06-09T09:32:28.03Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-05-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Antibiotics: Side Effects"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many and what proportion of patients who are prescribed fluoroquinolone antibiotics suffer adverse reactions in the form of (a) tendon injury, (b) mitochondrial dysfunction and (c) oxidative stress.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4025", "label" : {"_value" : "Biography information for Mrs Pauline Latham"} } , "tablingMemberConstituency" : {"_value" : "Mid Derbyshire"} , "tablingMemberPrinted" : [{"_value" : "Mrs Pauline Latham"} ], "uin" : "7154"} , {"_about" : "http://data.parliament.uk/resources/1327744", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1327744/answer", "answerText" : {"_value" : " The Yellow Card Scheme is the system used in the United Kingdom for reporting adverse drug reactions (ADRs). This acts as an early warning system for the identification of previously unrecognised adverse reactions and also provides valuable information on recognised ADRs, allowing the Commission on Human Medicines and Medicines and Healthcare products Regulatory Agency (MHRA) to identify and refine the understanding of risk factors that may affect the clinical management of patients.<\/p> <\/p> The following table shows spontaneous suspected ADR reports for fluoroquinolones in association with tendon injury, mitochondrial dysfunction and oxidative stress to 25 May 2021 in the UK.<\/p> <\/p>
|